Atrial Fibrillation. Stroke Prevention in Older Adults.

Clinics in Geriatric Medicine

Volumn 28, Issue 4, 2012, Pages 617-634

  Quinn, Gene R ^a   Fang, Margaret C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Bleeding risk; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; COX MAZE PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; GERIATRIC CARE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SURGERY; HUMAN; LEFT ATRIAL APPENDAGE PROCEDURE; LIVER TOXICITY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; SURGICAL TECHNIQUE; THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; RISK FACTORS; STROKE; WARFARIN;

EID: 84867927087     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2012.08.003     Document Type: Review

References (77)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22(8):983-988.
2. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285(18):2370-2375.
3. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006, 27(8):949-953.
4. Brass L.M., Krumholz H.M., Scinto J.M., et al. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28(12):2382-2389.
5. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114(7):e257-e354.
6. Naccarelli G.V., Varker H., Lin J., et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104(11):1534-1539.
7. Fang M.C., Go A.S., Chang Y., et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008, 51(8):810-815.
8. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271(11):840-844.
9. Elijovich L., Josephson S.A., Fung G.L., et al. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis 2009, 18(3):185-189.
10. Healey J.S., Connolly S.J., Gold M.R., et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012, 366(2):120-129.
11. Ivan C.S., Seshadri S., Beiser A., et al. Dementia after stroke: the Framingham Study. Stroke 2004, 35(6):1264-1268.
12. Lamassa M., Di Carlo A., Pracucci G., et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001, 32(2):392-398.
13. Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996, 27(10):1760-1764.
14. Jorgensen H.S., Nakayama H., Reith J., et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996, 27(10):1765-1769.
15. Wolf P.A., Dawber T.R., Thomas H.E., et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978, 28(10):973-977.
16. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347(23):1825-1833.
17. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e531S-e575S.
18. van Walraven C., Hart R.G., Singer D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288(19):2441-2448.
19. Halligan S.C., Gersh B.J., Brown R.D., et al. The natural history of lone atrial flutter. Ann Intern Med 2004, 140(4):265-268.
20. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110(16):2287-2292.
21. Van Staa T.P., Setakis E., Di Tanna G.L., et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011, 9(1):39-48.
22. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
23. Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137(2):263-272.
24. Chao T.F., Lin Y.J., Tsao H.M., et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011, 58(23):2380-2385.
25. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A.J., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31(19):2369-2429.
26. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327(20):1406-1412.
27. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343(8899):687-691.
28. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146(12):857-867.
29. Fang M.C., Go A.S., Chang Y., et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012, 43(7):1795-1799.
30. Singer D.E., Chang Y., Fang M.C., et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009, 2(4):297-304.
31. International Warfarin Pharmacogenetics Consortium, Klein T.E., Altman R.B., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360(8):753-764.
32. Chiquette E., Amato M.G., Bussey H.I. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998, 158(15):1641-1647.
33. Wilson S.J., Wells P.S., Kovacs M.J., et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003, 169(4):293-298.
34. Aziz F., Corder M., Wolffe J., et al. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011, 54(5):1404-1407.
35. Menendez-Jandula B., Souto J.C., Oliver A., et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005, 142(1):1-10.
36. Matchar D.B., Jacobson A., Dolor R., et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010, 363(17):1608-1620.
37. Albers G.W., Diener H.C., Frison L., et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293(6):690-698.
38. Albers G.W., Diener H.C., Frison L., et al. Trials and tribulations of noninferiority: the ximelagatran experience. J Am Coll Cardiol 2006, 48(5):1058. [author reply: 1059].
39. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
40. Legrand M., Mateo J., Aribaud A., et al. The use of dabigatran in elderly patients. Arch Intern Med 2011, 171(14):1285-1286.
41. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172(5):397-402.
42. Shah S.V., Gage B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011, 123(22):2562-2570.
43. Kamel H., Johnston S.C., Easton J.D., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012, 43(3):881-883.
44. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
45. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124(14):1573-1579.
46. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
47. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817.
48. Ruff C.T., Giugliano R.P., Antman E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160(4):635-641.
49. Turpie A.G., Bauer K.A., Davidson B.L., et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009, 101(1):68-76.
50. Flaker G.C., Gruber M., Connolly S.J., et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006, 152(5):967-973.
51. Gage B.F., Cardinalli A.B., Albers G.W., et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995, 274(23):1839-1845.
52. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367(9526):1903-1912. ACTIVE Writing Group of the ACTIVE Investigators.
53. ACTIVE Investigators, Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360(20):2066-2078.
54. Gentile F., Elhendy A., Khandheria B.K., et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002, 77(9):897-904.
55. Wazni O., Wilkoff B., Saliba W. Catheter ablation for atrial fibrillation. N Engl J Med 2011, 365(24):2296-2304.
56. Weerasooriya R., Khairy P., Litalien J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol 2011, 57(2):160-166.
57. Cox J.L., Ad N., Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999, 118(5):833-840.
58. Garcia-Fernandez M.A., Perez-David E., Quiles J., et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003, 42(7):1253-1258.
59. Ostermayer S.H., Reisman M., Kramer P.H., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005, 46(1):9-14.
60. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374(9689):534-542.
61. Hobbs F.D., Roalfe A.K., Lip G.Y., et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ 2011, 342:d3653.
62. Garcia D., Regan S., Crowther M., et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005, 127(6):2049-2056.
63. Copland M., Walker I.D., Tait R.C. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001, 161(17):2125-2128.
64. Perez-Gomez F., Iriarte J.A., Zumalde J., et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur Heart J 2007, 28(8):996-1003.
65. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370(9586):493-503.
66. Singer D.E., Chang Y., Fang M.C., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151(5):297-305.
67. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120(8):700-705.
68. Eckman M.H., Rosand J., Knudsen K.A., et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003, 34(7):1710-1716.
69. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105(2):91-99.
70. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151(3):713-719.
71. Lip G.Y., Frison L., Halperin J.L., et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57(2):173-180.
72. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58(4):395-401.
73. Man-Son-Hing M., Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003, 163(13):1580-1586.
74. Man-Son-Hing M., Nichol G., Lau A., et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159(7):677-685.
75. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40(6):675-683.
76. Sellers M.B., Newby L.K. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J 2011, 161(2):241-246.
77. Gage B.F., Birman-Deych E., Kerzner R., et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005, 118(6):612-617.